Flavin-Conjugated Pt(IV) Anticancer Agents

Area of Science:

• Medicinal Chemistry
• Inorganic Chemistry
• Cancer Therapeutics

Background:

• Platinum(IV) complexes offer a strategy to improve anticancer drug efficacy and reduce toxicity.
• In situ activation of Pt(IV) to Pt(II) species allows for controlled drug release.
• Classic platinum agents face challenges with off-target toxicity.

Purpose of the Study:

• To design and synthesize novel asymmetric Pt(IV) derivatives of cisplatin and oxaliplatin.
• To investigate the in situ activation of these Pt(IV) complexes.
• To evaluate the selective anticancer activity of the novel compounds.

Main Methods:

• Synthesis of Pt(IV) complexes 1·TARF and 2·TARF with a tetraacetylriboflavin (TARF) moiety.
• Characterization using 1H and 195Pt NMR spectroscopy.
• In vitro studies on MDA-MB-231 breast cancer cells with varying redox conditions.
• Density functional theory (DFT) for mechanistic insights.

Main Results:

• Pt(IV) complexes 1·TARF and 2·TARF were successfully synthesized and activated to Pt(II) species.
• Activation was confirmed using various reducing agents and conditions (dark/light).
• Complex 2·TARF showed enhanced toxicity (1-2 orders of magnitude) in breast cancer cells via redox activation, dependent on covalent TARF binding.

Conclusions:

• Covalently linked tetraacetylriboflavin moieties enable targeted in situ activation of Pt(IV) anticancer agents.
• Redox-triggered activation of 2·TARF leads to selective enhancement of cytotoxicity in cancer cells.
• The covalent linkage is crucial for achieving targeted drug activation and improved therapeutic effect.